Candidates for Strontium 89 therapy are typically patients with painful bone metastases, most commonly from primary cancers like prostate or breast cancer. It is generally considered when conventional pain management strategies, such as analgesics and external beam radiation therapy, are insufficient or cause significant side effects.
